TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Dec 31, 2024. Filed Feb 5, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 5, 2025
TEVA$42.97+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance sheets
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $3,300 | $3,226 |
| Accounts receivables, net of allowance for credit losses of $78 million and $95 million as of December 31, 2024 and December 31, 2023, respectively | 3,059 | 3,408 |
| Inventories | 3,007 | 4,021 |
| Prepaid expenses | 1,006 | 1,255 |
| Other current assets | 409 | 504 |
| Assets held for sale | 1,771 | 70 |
| Total current assets | 12,552 | 12,485 |
| Deferred income taxes | 1,799 | 1,812 |
| Other non-current assets | 462 | 470 |
| Property, plant and equipment, net | 4,581 | 5,750 |
| Operating lease right-of-use assets | 367 | 397 |
| Identifiable intangible assets, net | 4,418 | 5,387 |
| Goodwill | 15,147 | 17,177 |
| Total assets | $39,326 | $43,479 |
| LIABILITIES AND EQUITY | ||
| Current liabilities: | ||
| Short-term debt | $1,781 | $1,672 |
| Sales reserves and allowances | 3,678 | 3,535 |
| Accounts payables | 2,203 | 2,602 |
| Employee-related obligations | 624 | 611 |
| Accrued expenses | 2,792 | 2,771 |
| Other current liabilities | 1,020 | 1,044 |
| Liabilities held for sale | 698 | 13 |
| Total current liabilities | 12,796 | 12,247 |
| Long-term liabilities: | ||
| Deferred income taxes | 483 | 606 |
| Other taxes and long-term liabilities | 4,028 | 4,019 |
| Senior notes and loans | 16,002 | 18,161 |
| Operating lease liabilities | 296 | 320 |
| Total long-term liabilities | 20,809 | 23,106 |
| Total liabilities | 33,606 | 35,353 |
| Redeemable non-controlling interests | 340 | — |
| Equity: | ||
| Teva shareholders’ equity: | ||
| Ordinary shares of NIS 0.10 par value per share; December 31, 2024 and December 31, 2023: authorized 2,495 million shares; issued 1,240 million shares and 1,227 million shares, respectively | 58 | 57 |
| Additional paid-in capital | 27,764 | 27,807 |
| Accumulated deficit | (15,173) | (13,534) |
| Accumulated other comprehensive loss | (3,148) | (2,697) |
| Treasury shares as of December 31, 2024 and December 31, 2023: 107 million and 106 million ordinary shares, respectively | (4,128) | (4,128) |
| 5,373 | 7,506 | |
| Non-controlling interests | 7 | 620 |
| Total equity | 5,380 | 8,126 |
| Total liabilities, redeemable non-controlling interests and equity | $39,326 | $43,479 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.